Anuncia Medical Announces the First Successful US Implant of the Company's Newly Commercially Released ReFlow™ Mini Flusher Device for Hydrocephalus Patients
SCOTTSDALE, Ariz., Aug. 1, 2023 /PRNewswire/ -- Anuncia Medical Inc. ("Anuncia" or the "Company"), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company's FDA-cleared ReFlow™ Mini Flusher device.
- The second-generation, FDA-cleared ReFlow Mini Flusher is indicated for use in patients living with hydrocephalus or similar conditions.
- The reduced size and profile of the technology is designed to better support a broader hydrocephalus patient population, from infants to older adults.
- The first-generation ReFlow device was successfully implanted in over 30 patients with hydrocephalus and is the subject of 11 clinical studies/reports.
- It is expected that the ReFlow Mini Flusher will be available internationally in the future.